Anar al contingut
VuFind
    • English
    • Deutsch
    • Español
    • Français
    • Italiano
    • 日本語
    • Nederlands
    • Português
    • Português (Brasil)
    • 中文(简体)
    • 中文(繁體)
    • Türkçe
    • עברית
    • Gaeilge
    • Cymraeg
    • Ελληνικά
    • Català
    • Euskara
    • Русский
    • Čeština
    • Suomi
    • Svenska
    • polski
    • Dansk
    • slovenščina
    • اللغة العربية
    • বাংলা
    • Galego
    • Tiếng Việt
    • Hrvatski
    • हिंदी
    • Հայերէն
    • Українська
    • Sámegiella
    • Монгол
Avançada
  • Response to the letter by Prof...
  • Citar
  • Enviar aquest missatge de text
  • Enviar per correu electrònic aquest
  • Imprimir
  • Exportar registre
    • Exportar a RefWorks
    • Exportar a EndNoteWeb
    • Exportar a EndNote
  • Enllaç permanent
Response to the letter by Prof Jonathan Deeks to the Lancet EClinicalMedicine editor

Response to the letter by Prof Jonathan Deeks to the Lancet EClinicalMedicine editor

Dades bibliogràfiques
Autors principals: Leber, W, Lammel, O, Panovska-Griffiths, J, Czypionka, T
Format: Journal article
Idioma:English
Publicat: Elsevier 2021
  • Fons
  • Descripció
  • Ítems similars
  • Visualització del personal

Ítems similars

  • Response to the letter by Prof Jonathan Deeks to the Lancet EClinicalMedicine editor
    per: Werner Leber, et al.
    Publicat: (2021-10-01)
  • Corrigendum to ‘Oral Azvudine for hospitalised patients with COVID-19 and pre-existing conditions: a retrospective cohort study.’ [EClinicalMedicine 59 (2023) 101981]
    per: Yuming Sun, et al.
    Publicat: (2023-08-01)
  • Corrigendum to “Real-world long-term outcomes in individuals at clinical risk for psychosis: The case for extending duration of care” [EClinicalMedicine 28 (2020) 100,578]
    per: Paolo Fusar-Poli, et al.
    Publicat: (2021-02-01)
  • Corrigendum to Antiviral effect of high-dose ivermectin in adults with COVID-19: A proof-of-concept randomized trial [EClinicalMedicine 37 (2021) 100,959]”
    per: Alejandro Krolewiecki, et al.
    Publicat: (2021-09-01)
  • Corrigendum to “Nitazoxanide superiority to placebo to treat moderate COVID-19 – A Pilot prove of concept randomized double-blind clinical trial.” [EClinicalMedicine 37 (2021) 100981]
    per: Vinicius Fontanesi Blum, MD, MSc, et al.
    Publicat: (2021-11-01)

Opcions de cerca

  • Historial de cerca
  • Cerca avançada

Trobar-ne més

  • Explorar el catàleg
  • Explorar alfabèticament
  • Explora canals
  • Bibliografia recomanada
  • Nous ítems

Necessites ajuda?

  • Consells de cerca
  • Pregunteu al bibliotecari
  • FAQs